I-131-CLR1404

DRUG3 trials

Sponsors

Cellectar, Inc, Cellectar Biosciences, Inc.

Conditions

CancerMultiple MyelomaSolid Tumors

Phase 1

Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors

CompletedNCT00925275

Cellectar, IncSolid Tumors

Start: 2009-06-30End: 2010-02-28Target: 9Updated: 2010-05-04

Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

CompletedNCT01495663

Cellectar Biosciences, Inc.Cancer

Start: 2011-12-31End: 2014-01-31Updated: 2015-02-26

Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

CompletedNCT02278315

Cellectar Biosciences, Inc.Multiple Myeloma

Start: 2015-02-28End: 2022-08-10Updated: 2023-02-22

Related Papers

Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 (CLR 131) in Patients with Relapsed or Refractory Multiple Myeloma

Blood2019-11-135 citations

Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Blood2019-11-135 citations

Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Blood2016-12-021 citations

A Phase 1 Study of 131I-CLR1404 in Patients with Relapsed or Refractory Advanced Solid Tumors: Dosimetry, Biodistribution, Pharmacokinetics, and Safety

PLoS ONE2014-11-1726 citations

A phase 1 study of phospholipid ether [<sup>131</sup>I]-CLR1404 in patients with advanced solid tumors.

Journal of Clinical Oncology2014-05-20